$RMD
RESMED INC

2019 Q2 Form 10-Q Financial Statement

#000094381919000014 Filed on May 03, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue $705.0M $662.2M $591.6M
YoY Change 13.05% 11.93% 15.06%
Cost Of Revenue $302.5M $281.3M $247.3M
YoY Change 4.89% 13.71% 15.31%
Gross Profit $402.4M $381.0M $344.3M
YoY Change 20.05% 10.65% 14.88%
Gross Profit Margin 57.08% 57.53% 58.19%
Selling, General & Admin $171.6M $164.5M $147.9M
YoY Change 9.44% 11.25% 7.25%
% of Gross Profit 42.64% 43.19% 42.96%
Research & Development $51.10M $47.61M $37.43M
YoY Change 28.72% 27.18% 6.65%
% of Gross Profit 12.7% 12.5% 10.87%
Depreciation & Amortization $42.60M $41.70M $29.40M
YoY Change 34.38% 41.84% 3.16%
% of Gross Profit 10.59% 10.95% 8.54%
Operating Expenses $230.8M $224.0M $207.9M
YoY Change 27.65% 7.73% 12.76%
Operating Profit $171.6M $157.0M $136.4M
YoY Change 11.14% 15.11% 18.28%
Interest Expense -$18.70M $12.41M $7.719M
YoY Change 567.86% 60.81% -366.17%
% of Operating Profit -10.9% 7.91% 5.66%
Other Income/Expense, Net -$6.600M -$19.05M -$6.230M
YoY Change 53.49% 205.75% -278.0%
Pretax Income $95.80M $137.9M $130.1M
YoY Change -31.47% 5.98% 20.5%
Income Tax $27.00M $32.51M $20.02M
% Of Pretax Income 28.18% 23.57% 15.38%
Net Earnings $68.80M $105.4M $110.1M
YoY Change -36.71% -4.28% 25.43%
Net Earnings / Revenue 9.76% 15.92% 18.61%
Basic Earnings Per Share $0.74 $0.77
Diluted Earnings Per Share $474.8K $0.73 $0.76
COMMON SHARES
Basic Shares Outstanding 143.4M 143.3M 142.9M
Diluted Shares Outstanding 144.3M 144.0M

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $147.1M $146.5M $704.3M
YoY Change -22.05% -79.2% -14.87%
Cash & Equivalents $147.1M $146.5M $704.3M
Short-Term Investments
Other Short-Term Assets $110.3M $114.4M $113.0M
YoY Change -11.55% 1.24% 8.03%
Inventory $349.6M $319.9M $288.7M
Prepaid Expenses
Receivables $528.5M $511.4M $498.4M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.145B $1.103B $1.604B
YoY Change 7.47% -31.27% -0.06%
LONG-TERM ASSETS
Property, Plant & Equipment $387.5M $382.5M $398.0M
YoY Change 0.24% -3.9% 2.74%
Goodwill $1.856B $1.939B
YoY Change 73.67%
Intangibles
YoY Change
Long-Term Investments $21.67M $49.15M $41.15M
YoY Change 19.43%
Other Assets $151.0M $125.7M $222.7M
YoY Change -44.84% -43.54% 98.31%
Total Long-Term Assets $2.962B $2.996B $1.930B
YoY Change 48.25% 55.24% 6.2%
TOTAL ASSETS
Total Short-Term Assets $1.145B $1.103B $1.604B
Total Long-Term Assets $2.962B $2.996B $1.930B
Total Assets $4.108B $4.099B $3.534B
YoY Change 34.07% 15.97% 3.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $115.7M $124.5M $88.20M
YoY Change 24.81% 41.12% 6.52%
Accrued Expenses $266.4M $191.1M $193.5M
YoY Change 43.35% -1.22% 15.25%
Deferred Revenue $88.67M $82.29M
YoY Change 45.77%
Short-Term Debt $11.99M $12.35M $0.00
YoY Change 4.59%
Long-Term Debt Due $12.00M $12.30M
YoY Change 4.35%
Total Short-Term Liabilities $556.0M $463.0M $461.5M
YoY Change 8.75% 0.32% 37.23%
LONG-TERM LIABILITIES
Long-Term Debt $1.259B $1.323B $810.0M
YoY Change 366.26% 63.37% -30.67%
Other Long-Term Liabilities $2.058M $865.0K $183.0M
YoY Change 122.73% -99.53% 266.0%
Total Long-Term Liabilities $1.479B $1.614B $993.0M
YoY Change 199.68% 62.56% -18.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $556.0M $463.0M $461.5M
Total Long-Term Liabilities $1.479B $1.614B $993.0M
Total Liabilities $2.035B $2.077B $1.467B
YoY Change 102.55% 41.58% -6.4%
SHAREHOLDERS EQUITY
Retained Earnings $2.436B $2.421B
YoY Change 0.17%
Common Stock $1.511B $1.476B
YoY Change 4.18%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.623B $1.623B
YoY Change 1.43%
Treasury Stock Shares $41.84M $41.84M
Shareholders Equity $2.072B $2.021B $2.067B
YoY Change
Total Liabilities & Shareholders Equity $4.108B $4.099B $3.534B
YoY Change 34.07% 15.97% 3.26%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income $68.80M $105.4M $110.1M
YoY Change -36.71% -4.28% 25.43%
Depreciation, Depletion And Amortization $42.60M $41.70M $29.40M
YoY Change 34.38% 41.84% 3.16%
Cash From Operating Activities $141.9M $139.6M $149.1M
YoY Change 9.66% -6.37% 120.56%
INVESTING ACTIVITIES
Capital Expenditures -$24.20M -$17.00M -$15.10M
YoY Change 22.22% 12.58% -10.65%
Acquisitions
YoY Change
Other Investing Activities -$19.60M -$208.5M -$4.500M
YoY Change 4.26% 4533.33% 350.0%
Cash From Investing Activities -$43.90M -$225.4M -$19.60M
YoY Change 14.03% 1050.0% 9.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -97.60M 83.20M -276.5M
YoY Change -83.42% -130.09% 421.7%
NET CHANGE
Cash From Operating Activities 141.9M 139.6M 149.1M
Cash From Investing Activities -43.90M -225.4M -19.60M
Cash From Financing Activities -97.60M 83.20M -276.5M
Net Change In Cash 400.0K -2.600M -147.0M
YoY Change -100.08% -98.23% 4354.55%
FREE CASH FLOW
Cash From Operating Activities $141.9M $139.6M $149.1M
Capital Expenditures -$24.20M -$17.00M -$15.10M
Free Cash Flow $166.1M $156.6M $164.2M
YoY Change 11.33% -4.63% 94.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000943819
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
143392631
CY2018Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
247339000
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
270318000
us-gaap Revenues
Revenues
1901608000
CY2019Q1 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
125999000
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
RESMED INC
dei Entity Small Business
EntitySmallBusiness
false
dei Trading Symbol
TradingSymbol
rmd
rmd Amortization Of Acquired Intangible Assets1
AmortizationOfAcquiredIntangibleAssets1
34772000
CY2018Q1 rmd Amortization Of Acquired Intangible Assets1
AmortizationOfAcquiredIntangibleAssets1
11673000
rmd Amortization Of Acquired Intangible Assets1
AmortizationOfAcquiredIntangibleAssets1
51501000
CY2019Q1 rmd Amortization Of Acquired Intangible Assets1
AmortizationOfAcquiredIntangibleAssets1
22794000
rmd Business Acquisition Contingent Consideration Recognized Liability
BusinessAcquisitionContingentConsiderationRecognizedLiability
167000
rmd Organization And Basis Of Presentation Policy Text Bock
OrganizationAndBasisOfPresentationPolicyTextBock
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;">Organization and Basis of Presentation</font> </p> <p style="margin:0pt;text-indent:0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt"> <font style="display: inline;font-size:5pt;">&#xFEFF;</font> </p> <p style="margin:0pt;text-indent:0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">ResMed Inc. (referred to herein as &#x201C;we&#x201D;, &#x201C;us&#x201D;, &#x201C;our&#x201D; or the &#x201C;Company&#x201D;) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group.&nbsp;&nbsp;Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea.&nbsp;&nbsp;Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States.&nbsp;&nbsp;Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Norway and Sweden.</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt"> <font style="display: inline;font-size:5pt;">&#xFEFF;</font> </p> <p style="margin:0pt;text-indent:0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201C;U.S. GAAP&#x201D;) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (&#x201C;SEC&#x201D;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.&nbsp;&nbsp;In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June&nbsp;30, </font><font style="display: inline;">2019</font><font style="display: inline;">.</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt"> <font style="display: inline;font-size:5pt;">&#xFEFF;</font> </p> <p style="margin:0pt;text-indent:0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The condensed consolidated financial statements for the </font><font style="display: inline;">three and nine months ended March&nbsp;31, 2019</font><font style="display: inline;"> and </font><font style="display: inline;">March&nbsp;31, 2018</font><font style="display: inline;"> are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended </font><font style="display: inline;">June&nbsp;30, 2018</font><font style="display: inline;">.</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2018Q2 rmd Provision For Doubtful Debts
ProvisionForDoubtfulDebts
2277000
CY2019Q1 rmd Provision For Doubtful Debts
ProvisionForDoubtfulDebts
1347000
rmd Receivables Sold Amount
ReceivablesSoldAmount
72427000
rmd Receivables Sold Amount
ReceivablesSoldAmount
99693000
CY2018Q2 rmd Short Term Borrowings Gross
ShortTermBorrowingsGross
12000000
CY2019Q1 rmd Short Term Borrowings Gross
ShortTermBorrowingsGross
12367000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
92723000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
124466000
CY2018Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
483681000
CY2019Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
511403000
CY2018Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
160427000
CY2019Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
52739000
CY2018Q2 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
138102000
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
185805000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
191130000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
474314000
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
505848000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-224328000
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-252818000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1450821000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1476099000
CY2018Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
19258000
CY2019Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
25543000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
125995
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
239020
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
161314
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
356583
CY2018Q2 us-gaap Assets
Assets
3063923000
CY2019Q1 us-gaap Assets
Assets
4098526000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
1065717000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
1102696000
CY2018Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
1998206000
CY2019Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
2995830000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
6123000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
383000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-272000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
821935000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
704281000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188701000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
146513000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-117654000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-42188000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.35
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.74
CY2019Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.37
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.004
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.004
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
184315866
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
185182206
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
142679632
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
143345972
CY2018Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
571000
CY2019Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
573000
CY2018Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
60828000
CY2019Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
82288000
CY2018Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
71596000
CY2019Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
76703000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
716874000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
782874000
CY2018Q3 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
-188798000
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
132200000
CY2018Q1 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
5400000
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
4500000
CY2019Q1 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
3300000
CY2018Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
272000000
CY2019Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1327000000
CY2018Q2 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
281454000
CY2019Q1 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
1335695000
CY2018Q2 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
534000
CY2019Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
21000
CY2018Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2012000
CY2019Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
3651000
CY2018Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
53818000
CY2019Q1 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
32015000
CY2018Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
13084000
CY2019Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
87312000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
88256000
CY2017Q3 us-gaap Dividends
Dividends
49698000
CY2017Q4 us-gaap Dividends
Dividends
49856000
CY2018Q1 us-gaap Dividends
Dividends
49973000
CY2018Q3 us-gaap Dividends
Dividends
52794000
CY2018Q4 us-gaap Dividends
Dividends
52773000
CY2019Q1 us-gaap Dividends
Dividends
53024000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.44
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.35
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.43
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.76
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.33
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
us-gaap Goodwill Other Increase Decrease
GoodwillOtherIncreaseDecrease
247000
CY2018Q2 us-gaap Guarantee Obligations Maximum Exposure
GuaranteeObligationsMaximumExposure
29378000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
8060000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-5821000
CY2017Q2 us-gaap Equity Method Investments
EquityMethodInvestments
38324000
CY2018Q1 us-gaap Equity Method Investments
EquityMethodInvestments
41149000
CY2018Q2 us-gaap Equity Method Investments
EquityMethodInvestments
41226000
CY2019Q1 us-gaap Equity Method Investments
EquityMethodInvestments
49146000
us-gaap Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
us-gaap Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
5000000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
-14471000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
-27880000
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
215184000
CY2019Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
516450000
us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
1909000
CY2018Q2 us-gaap Goodwill
Goodwill
1068944000
CY2019Q1 us-gaap Goodwill
Goodwill
1939136000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-9227000
us-gaap Goodwill Other Increase Decrease
GoodwillOtherIncreaseDecrease
879419000
us-gaap Gross Profit
GrossProfit
999692000
CY2018Q1 us-gaap Gross Profit
GrossProfit
344295000
us-gaap Gross Profit
GrossProfit
1118734000
CY2019Q1 us-gaap Gross Profit
GrossProfit
391910000
CY2019Q1 us-gaap Guarantee Obligations Maximum Exposure
GuaranteeObligationsMaximumExposure
33558000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2014000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
3620000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
8801000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
130143000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
423082000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
137929000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-9371000
CY2019Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-5996000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
75119000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
211816000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20018000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87291000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32513000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
164540000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-106671000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
39421000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1482000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
11146000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
55002000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
72332000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
17453000
CY2018Q1 us-gaap Interest Expense
InterestExpense
7719000
us-gaap Interest Expense
InterestExpense
23608000
CY2019Q1 us-gaap Interest Expense
InterestExpense
12413000
us-gaap Interest Paid Net
InterestPaidNet
22873000
us-gaap Interest Paid Net
InterestPaidNet
23608000
CY2018Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
190833000
CY2019Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
237507000
CY2018Q2 us-gaap Inventory Net
InventoryNet
268701000
CY2019Q1 us-gaap Inventory Net
InventoryNet
319930000
CY2018Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
75415000
CY2019Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
79944000
CY2018Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2453000
CY2019Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2479000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
4228000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
415000
CY2018Q2 us-gaap Liabilities
Liabilities
1004943000
CY2018Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13117000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
156977000
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
273710000
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
125733000
CY2017Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
36389000
CY2017Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4450000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7393000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12872000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2501000
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
924000
CY2019Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
865000
CY2019Q1 us-gaap Liabilities
Liabilities
2077197000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3063923000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4098526000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
511249000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
462969000
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
493694000
CY2019Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1614228000
CY2018Q2 us-gaap Long Term Debt
LongTermDebt
269988000
CY2019Q1 us-gaap Long Term Debt
LongTermDebt
1323349000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-438026000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
678218000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-63298000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1031818000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
375610000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
317233000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
86125000
us-gaap Net Income Loss
NetIncomeLoss
205777000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
9527000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
110125000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
105737000
us-gaap Net Income Loss
NetIncomeLoss
335791000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
124639000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
105416000
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
55000
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
7568000
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
290000
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
400804000
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
320923000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6230000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-35105000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-19048000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
207922000
us-gaap Operating Expenses
OperatingExpenses
660547000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
234933000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
136373000
us-gaap Operating Income Loss
OperatingIncomeLoss
458187000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2739000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4140000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1054000
us-gaap Payments For Proceeds From Derivative Instrument Investing Activities
PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
4667000
us-gaap Payments For Proceeds From Derivative Instrument Investing Activities
PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
-3902000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
27897000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
22844000
us-gaap Payments Of Dividends
PaymentsOfDividends
149527000
us-gaap Payments Of Dividends
PaymentsOfDividends
158592000
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
205000
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
648000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
482000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
951565000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
482000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
951565000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
6743000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
6556000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6445000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
31092000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44961000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46507000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
124634000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
124850000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24074000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15346000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
120000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1414230000
CY2017Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
19558000
CY2018Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
19949000
CY2018Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
19227000
CY2019Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
19633000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
13135000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
10790000
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
13041000
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
11601000
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
860864000
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
888344000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
386550000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
382496000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
390000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
541394000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
115492000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37434000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
129513000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47610000
us-gaap Restructuring Charges
RestructuringCharges
10922000
CY2018Q1 us-gaap Restructuring Charges
RestructuringCharges
10922000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2432328000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2420731000
us-gaap Revenues
Revenues
1716566000
CY2018Q1 us-gaap Revenues
Revenues
591634000
CY2019Q1 us-gaap Revenues
Revenues
662228000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
60.48
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
70.57
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y4M24D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
46.41
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
52.02
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
102.12
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
443559000
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
147893000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
473410000
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
164529000
us-gaap Share Based Compensation
ShareBasedCompensation
35933000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
57.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
183
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
306842
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1205826
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1409385
CY2019Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
102.12
CY2019Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
848075
CY2018Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
11466000
CY2019Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
12346000
us-gaap Standard And Extended Product Warranty Accrual Foreign Currency Translation Gain Loss
StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss
-485000
us-gaap Standard And Extended Product Warranty Accrual Foreign Currency Translation Gain Loss
StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss
405000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
1960266000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
2049528000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
2019528000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
2066964000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
2058980000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
1900256000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1956044000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
2021329000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
103100
CY2017Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8653000
CY2018Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
10576000
CY2017Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-195000
CY2017Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-13658000
CY2018Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-862000
CY2018Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-141000
CY2018Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-27341000
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-330000
CY2017Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11959000
CY2017Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11997000
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11890000
CY2018Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12476000
CY2018Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12541000
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12828000
CY2017Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4682000
CY2017Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7428000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3006000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
513000
CY2018Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1263000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2896000
CY2019Q1 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
12900000
CY2018Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
41636234
CY2019Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
41836234
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
300000
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
200000
CY2018Q2 us-gaap Treasury Stock Value
TreasuryStockValue
1600412000
CY2019Q1 us-gaap Treasury Stock Value
TreasuryStockValue
1623256000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
27900000
CY2017Q4 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
8541000
CY2018Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
19357000
CY2018Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
22845000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
22800000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1207000
CY2018Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1087000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1437000
CY2019Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1017000
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
143985000.00
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
144344000.00
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
144333000.00
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
142688000
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
142898000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
142907000
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
143316000

Files In Submission

Name View Source Status
0000943819-19-000014-index-headers.html Edgar Link pending
0000943819-19-000014-index.html Edgar Link pending
0000943819-19-000014.txt Edgar Link pending
0000943819-19-000014-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rmd-20190331.xml Edgar Link completed
rmd-20190331.xsd Edgar Link pending
rmd-20190331x10q.htm Edgar Link pending
rmd-20190331xex31_1.htm Edgar Link pending
rmd-20190331xex31_2.htm Edgar Link pending
rmd-20190331xex32.htm Edgar Link pending
rmd-20190331_cal.xml Edgar Link unprocessable
rmd-20190331_def.xml Edgar Link unprocessable
rmd-20190331_lab.xml Edgar Link unprocessable
rmd-20190331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending